Magnolia Medical Technologies said yesterday it launched its Steripath Gen2 blood collection system.
The next-generation device features mechanical initial specimen diversion and improved usability based on input from end users, the Seattle-based company said.
“Our team is very pleased with the 83 percent reduction in blood culture contamination we have achieved using Steripath. Based on this success, we are now expanding and standardizing its use throughout all Lee Health hospitals,” Jessica Plante of Lee Health said in a press release.
“At Magnolia, we are committed to eliminating blood culture contamination by empowering healthcare providers with the advanced technologies they need to significantly reduce false positive diagnostic results for sepsis, and the associated patient safety risks, global antibiotic resistance implications and avoidable costs to our healthcare system. Our customers have demonstrated reproducible, sustained results in hospital settings ranging from large academic and government institutions to small community hospitals. We look forward to continued partnership and support of our hospital customers in establishing a new standard of care in sepsis testing accuracy,” CEO Greg Bullington said in a prepared statement.
Last April, Magnolia Medical Tech said that it raised $7.3 million in a round of funding to support its Steripath blood collection system.
